Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

TSX:NWC
TSX:NWCConsumer Retailing

Does North West’s Recent 10% Price Rise Reflect Its True Value in 2025?

If you are wondering whether North West is still attractively priced today or whether the market has already incorporated most of the potential upside, this is a good place to unpack what the numbers are really indicating. The stock has inched up 0.8% over the last week and 9.6% over the last month. That compares with a modest 1.4% gain year to date and a slightly negative 1 year return of -2.3%, following a stronger 3 year and 5 year performance of 53.7% and 78.6% respectively. Recent moves...
ASX:JMS
ASX:JMSMetals and Mining

3 ASX Penny Stocks With Market Caps Larger Than A$10M

Australian shares are poised for further gains this week, buoyed by a surge in copper prices, with the ASX futures indicating an upward trend. While penny stocks might seem like a throwback to earlier trading days, they remain relevant for investors seeking opportunities beyond the well-known giants. These smaller or newer companies can offer surprising value when backed by solid financial foundations, and we've identified three such stocks on the ASX that combine balance sheet strength with...
NYSE:K
NYSE:KFood

Does Kellanova’s Snacks Focus Justify Its Strong Multi Year Share Price Gains?

Wondering if Kellanova is still fairly priced after its long run, or if there is more upside left in the tank? This breakdown will help you decide whether the current share price actually makes sense. The stock has been mostly treading water in the short term, down 0.6% over the last week and roughly flat over the past month at 0.1%. However, that hides a steadier climb of 2.6% year to date and 6.2% over the last year, compounding into 32.5% and 69.5% gains over the past 3 and 5...
NYSE:TJX
NYSE:TJXSpecialty Retail

TJX (TJX) Q3: Strong 5% Same-Store Sales Growth Tests Justification for Premium Valuation

TJX Companies (TJX) just posted another solid quarter, with Q3 2026 revenue of about $15.1 billion, Basic EPS of $1.28, and net income of $1.4 billion setting the tone for its latest update. The company has seen revenue move from roughly $14.1 billion and EPS of $1.15 in Q3 2025 to $15.1 billion and $1.28 this quarter, while trailing twelve month revenue has climbed to about $59.0 billion alongside EPS of $4.58 and net income of $5.1 billion, giving investors a clear view of steady top and...
NasdaqGM:TBPH
NasdaqGM:TBPHPharmaceuticals

Is Oppenheimer’s Focus on Ampreloxetine Quietly Redefining Theravance Biopharma’s (TBPH) Risk-Reward Profile?

Oppenheimer recently initiated coverage on Theravance Biopharma with an Outperform rating, emphasizing the importance of the Phase 3 ampreloxetine readout expected in the first quarter of 2026 and the company’s virtual key opinion leader event on this program. The focus on ampreloxetine as a potential billion-dollar therapy in a rare neurogenic condition highlights how pivotal this single late-stage asset has become for Theravance’s future prospects and risk profile. We’ll now explore how...
TSX:ATRL
TSX:ATRLConstruction

Is It Too Late to Consider AtkinsRéalis After Its Big Multi Year Share Price Surge?

If you have been wondering whether AtkinsRéalis Group is still good value after its huge run up, you are not alone. This stock has become a favorite talking point for investors trying to separate momentum from true underlying worth. Even after pulling back around 11.4% over the last month and slipping 0.4% in the past week, the share price is still up 16.0% year to date, 13.2% over the last year and an impressive 254.5% over three years and 279.4% over five years. This naturally raises the...